Analysis for ELV

📈 Growth & Financial Trajectory

Eight quarters show a steady top-line rise from about $43.9B in 2024-Q2 to about $50.2B in 2026-Q1, a gain of roughly $6.3B (~14%). Net income progressed from roughly $1.01B to about $1.76B, though a mid-period dip in 2024-Q4 (~$0.41B) underscores earnings volatility. Gross profit remained highly scalable, with margins around the 89%–91% band, supporting a robust revenue base even as quarterly earnings fluctuated. Operating margins hovered toward the mid-single digits in late 2025 and early 2026 (e.g., 2026-Q1 ~4.2%), reflecting ongoing cost management alongside revenue gains. Net cash from operating activities was consistently positive, e.g., $4.33B in 2026-Q1, signaling durable cash flow backing the earnings trend.

💰 Margins & Cash Flow

Upward revenue trend accompanied by very strong gross margins (~89%–91%). Operating margin improved through late 2025 into 2026-Q1 (around 4%–6% range), indicating better operating leverage despite higher operating costs in some quarters. Net cash flow from operating activities remained positive across the period, with notable strength in 2026-Q1 ($4.33B flow from operations). Cash flow from investing activities was typically negative, while financing activity flows varied by quarter.

🛡️ Balance Sheet & Liquidity

Balance sheet size remains solid, with assets near $120B and liabilities around $80B in mid-range quarters. Current assets generally sat around $63B–$67B and current liabilities near $41B–$45B, yielding a healthy current ratio ~1.5x. Long-term debt has been in the low-$30B range, and equity attributable to parent sits in the mid-to-high $40B range, suggesting a stable capital base and resilience against short-term shocks.

⚠️ Key Drivers & Risks

• Drivers: Aging/population trends driving demand for health coverage; strong top-line growth supports margin resilience.
• Risks: Earnings volatility due to benefit costs and healthcare costs, and regulatory/compliance shifts that could impact margin sensitivity.